EDVA NYSE Beverages Financials FY2016βFY2025
Endovia Health Sciences, Inc. had $0.1M of revenue in fiscal 2025, down 90.9% on the year before. Over five years, revenue changed β49.8% a year on average.
Last close Β· Oct 23, 2026
$0.16
7.2%Hi! I read Endovia Health Sciences, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β90.9%
No. Sales fell 90.9% last year.
Does it make a profit?
β34,520.9%
No. It lost money last year.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Endovia Health Sciences, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 18, 2026
Wednesday Β· in 23 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 19, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 20, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Apr 15, 2026 | Q4 '25 | After the market closes | 10-K β |
| Nov 19, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 10-Q β |
| Jul 11, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Jul 11, 2025 | Q4 '24 | After the market closes | 10-K β |
| Nov 15, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Endovia Health Sciences, Inc. had $0.1M of revenue in fiscal 2025, down 90.9% on the year before. Over five years, revenue changed β49.8% a year on average. Its operating margin was β19,406.6%, down 18,171.0Β pts: of every 100 in sales, about β19,407 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Endovia Health Sciences, Inc. lost $25.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Endovia Health Sciences, Inc. has $0.3M more cash than debt.
Cash, debt and the ratios that show how comfortably Endovia Health Sciences, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.2M | $4.4M | $0.4M | $0.0M | $0.3M |
| Debt incl. finance leases | $0.0M | $2.5M | $0.5M | $2.0M | $0.0M |
| Debt / equity | 0.0x | 0.3x | β | β | β |
| Interest coverage | β65.7x | β85.1x | β8.2x | β2.7x | β5.6x |
| Current ratio | 1.3x | 2.1x | 0.3x | 0.1x | 0.0x |
| Quick ratio | 1.0x | 1.4x | 0.1x | 0.1x | 0.0x |
| Total assets | $16.4M | $17.3M | $9.9M | $2.8M | $1.0M |
| Total liabilities | $7.5M | $8.0M | $15.5M | $21.4M | $16.3M |
| Shareholders' equity | $8.9M | $9.3M | β$5.6M | β$18.6M | β$15.3M |
| Net debt (β = net cash) | β$4.2M | β$1.9M | $0.1M | $2.0M | β$0.3M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Endovia Health Sciences, Inc. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 9 | 6 / 9 | 2 / 9 | 5 / 9 | 6 / 9 | 4 / 9 | 4 / 9 | 1 / 9 | 3 / 9 |
| Accruals ratio | β22.8% | β43.6% | 1.8% | β488.8% | β149.7% | β112.1% | β45.4% | β79.5% | β260.0% | β1,096.1% |
| Altman Z'' | β2.31 | β11.78 | β21.79 | β329.70 | β37.94 | β27.98 | β26.09 | β61.81 | β250.67 | β819.92 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.0M | $0.9M | $1.3M | $0.0M | $2.3M | $11.3M | $18.1M | $18.9M | $0.8M | $0.1M |
| Net interest income | β | β | β | β$0.7M | β$2.0M | β$0.4M | β | β$1.9M | β$3.7M | β$2.5M |
| Gross profit | $0.5M | $0.5M | $0.7M | β$0.2M | $0.4M | $3.9M | $5.9M | $5.6M | β$0.1M | $0.0M |
| Operating income | β$0.1M | β$0.2M | $0.1M | β$4.5M | β$17.7M | β$29.1M | β$21.4M | β$15.3M | β$9.9M | β$14.2M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.0M | β | $0.4M | $0.3M | $1.9M | $3.7M | $2.5M |
| Pretax income | β$0.0M | β$0.1M | $0.1M | β$0.5M | β | β | β | β | β | β |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$0.0M | β$0.1M | $0.1M | β$5.1M | β$28.7M | β$29.1M | β$21.7M | β$21.0M | β$23.8M | β$25.2M |
| Net income to common | β | β | β | β | β$28.7M | β$29.1M | β$21.7M | β | β | β |
| Diluted EPS | $0.00 | β$0.01 | $0.01 | β$0.04 | β$1.06 | β$1.02 | β | β | β$17.68 | β$11.97 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.02B | 0.03B | 0.04B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | $0.0M | β$0.0M | $0.1M | β$2.7M | β$21.3M | β$14.7M | β$14.0M | β$10.2M | β$7.3M | β$4.8M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | β |
| Free cash flow | β$0.0M | β$0.1M | β$0.0M | β$2.7M | β$21.4M | β$14.7M | β$14.1M | β$10.2M | β$7.3M | β |
| Depreciation and amortization | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.1M | $0.9M | $0.5M | $0.4M | $0.0M |
| Stock-based compensation | β | β | $0.0M | $1.6M | $2.3M | $4.0M | $7.4M | $1.2M | $2.4M | $8.6M |
| Acquisitions | β | β | β | β | $0.5M | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.1M | $0.0M | $0.9M | $0.0M | $0.4M | $4.2M | $4.4M | $0.4M | $0.0M | $0.3M |
| Total debt | $0.0M | $0.0M | $0.0M | $0.0M | $1.2M | $0.0M | $2.5M | $0.5M | $2.0M | $0.0M |
| Current assets | $0.3M | $0.2M | $0.3M | $0.4M | $2.2M | $8.3M | $10.7M | $4.0M | $1.9M | $0.6M |
| Current liabilities | $0.3M | $0.3M | $0.4M | $10.3M | $5.4M | $6.5M | $5.0M | $14.8M | $19.4M | $16.3M |
| Inventory | β | β | $0.0M | $0.3M | $0.8M | $1.9M | $3.7M | $2.3M | $0.3M | $0.0M |
| Property and equipment, net | $0.1M | $0.0M | $0.1M | $0.0M | $0.7M | $0.6M | $0.5M | $0.3M | $0.0M | $0.0M |
| Goodwill | β | β | β | β | $5.7M | $0.3M | $0.3M | $0.3M | β | β |
| Intangible assets | β | β | β | β | β | $5.6M | $4.9M | $4.5M | β | β |
| Total assets | $0.4M | $0.2M | $0.4M | $0.6M | $9.2M | $16.4M | $17.3M | $9.9M | $2.8M | $1.0M |
| Total liabilities | $0.3M | $0.3M | $0.4M | $10.4M | $9.3M | $7.5M | $8.0M | $15.5M | $21.4M | $16.3M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Shareholders' equity | $0.0M | β$0.1M | β$7.8M | β$9.8M | β$9.4M | $8.9M | $9.3M | β$5.6M | β$18.6M | β$15.3M |
| Margins | ||||||||||
| Gross margin | 52.1% | 50.8% | 53.8% | β1,103.4% | 15.8% | 34.6% | 32.7% | 29.5% | β15.0% | 23.1% |
| Operating margin | β4.9% | β17.6% | 5.1% | β21,995.6% | β767.9% | β257.0% | β118.3% | β81.1% | β1,235.5% | β19,406.6% |
| EBITDA margin | 0.6% | β9.5% | 9.9% | β21,950.0% | β762.9% | β256.0% | β113.1% | β78.2% | β1,185.4% | β19,393.8% |
| Net margin | β4.8% | β16.5% | 5.2% | β25,175.0% | β1,246.7% | β256.7% | β119.9% | β111.4% | β2,964.8% | β34,520.9% |
| FCF margin | β2.6% | β8.5% | β1.0% | β13,092.6% | β930.7% | β129.9% | β78.2% | β54.1% | β911.8% | β |
| Net interest share of revenue | β | β | β | β3,260.8% | β86.1% | β3.9% | β | β9.8% | β461.8% | β3,451.8% |
| Returns | ||||||||||
| Return on capital | β278.2% | β | β | β | β | β489.7% | β227.6% | β | β | β |
| Return on capital employed | β77.0% | 266.9% | 2,382.1% | 46.4% | β463.5% | β293.6% | β173.4% | 315.1% | 59.6% | 92.8% |
| Return on equity | β122.9% | β | β | β | β | β | β238.4% | β1,130.2% | β | β |
| Return on assets | β13.7% | β49.5% | 21.0% | β1,013.4% | β583.3% | β226.9% | β128.8% | β154.4% | β375.4% | β1,354.9% |
| Return on tangible equity | β122.9% | β | β | β | β | β964.5% | β514.7% | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β11.6% | 46.2% | β98.4% | 11,175.0% | 392.0% | 59.8% | 4.2% | β95.7% | β90.9% |
| Net income growth | β | β | β | β7,630.4% | β | β | β | β | β | β |
| EPS growth | β | β | β | β500.0% | β | β | β | β | β | β |
| Share count change | β | 7.5% | 1.0% | 4.8% | 55.3% | 55.9% | 29.4% | β97.2% | 26.1% | 62.8% |
| Financial health | ||||||||||
| Net debt / EBITDA | β4.4x | β | β7.1x | β | β | β | β | β | β | β |
| Debt / equity | 0.9x | β | β | β | β | 0.0x | 0.3x | β | β | β |
| Interest coverage | β10.6x | β34.9x | 11.7x | β534.2x | β | β65.7x | β85.1x | β8.2x | β2.7x | β5.6x |
| Current ratio | 1.0x | 0.6x | 0.9x | 0.0x | 0.4x | 1.3x | 2.1x | 0.3x | 0.1x | 0.0x |
| Quick ratio | 1.0x | 0.6x | 0.8x | 0.0x | 0.3x | 1.0x | 1.4x | 0.1x | 0.1x | 0.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 5.8% | 6.5% | 5.8% | 61.8% | 4.0% | 0.0% | 0.6% | 0.1% | 0.4% | β |
| Stock comp / revenue | β | β | 0.0% | 7,941.7% | 101.3% | 35.1% | 41.0% | 6.2% | 294.1% | 11,796.9% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 6.0 | 2.0 | 5.0 | 6.0 | 4.0 | 4.0 | 1.0 | 3.0 |
| Altman Z'' | β2.3 | β11.8 | β21.8 | β329.7 | β37.9 | β28.0 | β26.1 | β61.8 | β250.7 | β819.9 |
| Accruals ratio | β22.8% | β43.6% | 1.8% | β488.8% | β149.7% | β112.1% | β45.4% | β79.5% | β260.0% | β1,096.1% |
Source: SEC EDGAR XBRL filings (CIK 0001553788). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.